A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)

NCT00000742 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Atevirdine mesylate
DRUG: Zidovudine
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]